



## **St. Paul's Hospital Heart Centre in Vancouver Obtains VMS Heart Analysis System**

### **Clinical Group to Study Advantages of VMS in Managing Adult Heart Patients**

Wednesday, June 29, 2011

**SEATTLE, WASHINGTON--(Marketwire - June 29, 2011)** - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT)(PINK SHEETS:VPTDF) as part of its controlled rollout strategy, is pleased to announce an additional installation of its VentriPoint Medical System (VMS™) at the St. Paul's Hospital in Vancouver, Canada. The adult congenital heart disease (ACHD) group at St. Paul's Hospital will initially use the VMS™ to monitor adult patients who have had surgery for congenital heart disease, but still have significant heart problems and life-long monitoring of the right ventricle.

"We are pleased to collaborate with VentriPoint in the assessment and on-going development of the VMS™ in our hospital," said Dr. Marla Kiess, Director of the Pacific Adult Congenital Heart Clinic and Medical Director of the Echo Laboratory at St. Paul's Hospital. Dr. Jasmine Grewal, adult congenital heart disease cardiologist and lead investigator for the project added, "The VMS™ has the potential to improve patient care and outcomes by providing physicians with a tool to monitor right ventricular function in ACHD patients that is highly accurate, easily accessible and at a lower cost than the diagnostic tools currently in use."

VentriPoint's CEO, Dr. George Adams, commented, "This is our first installation for adult patients in Canada. The St. Paul's cardiology group has defined a number of research projects and will be advancing our knowledge of right heart remodeling by studying adults with congenital heart disease."

Vancouver's St. Paul's Hospital is the seventh announced installation of the VMS™ heart analysis system. There are currently three systems in Canada (two children and one adult), one adult system in Europe and three systems in the United States. The company is scheduled to have nine systems installed by the end of June and the tenth system installed shortly thereafter. The last three installations will be announced once the hospitals have approved the press releases.

Given the overwhelming level of interest in response to the Company's initial exhibitions at the meetings of the European Association of Pediatric Cardiologists, in Granada, May 18-21 and the American Society of Echocardiology, Montreal, June 14-18 and its attendance at the International Society of Adult Congenital Heart Disease, Cincinnati, June 19-22, the Company has commenced the assembly of five additional VMS™ machines for installation during the next few months. There has been significant interest in the acquisition of the VMS™ for clinical use in Canada and Europe where the product has received regulatory approval. Additionally, VentriPoint has engaged leading investigators and opinion leaders in collaborative projects to validate the pulmonary hypertension application, acquire pivotal trial data for US-FDA 510(k) approval and begin development of new applications in response to clinical and market needs. The VMS™ installations anticipated through the end of 2011 will be at premier institutions around the world for both clinical use and synergistic research projects.

#### **About St. Paul's Hospital**

As a teaching hospital affiliated with the University of British Columbia, basic health research at St. Paul's has a cardiovascular, pulmonary & critical care focus — complementing a number of the priority clinical service areas. St. Paul's is designated the provincial Heart Centre, offering services ranging from prevention and rehabilitation to heart transplantation. Working in affiliation with the cardiac programs at Vancouver Hospital, Children's and Women's Health Centre of British Columbia within the Vancouver Coastal Health Authority, the St. Paul's Heart Centre is a resource for all British Columbians.

#### **About VentriPoint Diagnostics Ltd:**

VentriPoint creates diagnostic systems to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a \$10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration. For further information about VentriPoint go to [www.ventripoint.com](http://www.ventripoint.com).

**Cautionary Note Regarding Forward-Looking Statements** - Certain statements contained herein constitute forward-looking statements, including statements concerning the anticipated closing date of the Offering and the anticipated use of proceeds. We believe the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein

should not be unduly relied upon. Closing could be delayed if VentriPoint cannot obtain necessary regulatory approvals within anticipated timelines and will not be completed unless certain conditions customary for transactions of this kind are satisfied. The forward-looking statements included in this press release are made as of the date of this press release and VentriPoint disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

**For further information contact:**

Ventripoint Diagnostics .  
George Adams  
President & CEO  
Ph: (403) 283-0221  
Fax: (403) 283-2309  
[info@ventripoint.com](mailto:info@ventripoint.com)  
[www.ventripoint.com](http://www.ventripoint.com)

The Howard Group Inc.  
Peter Weichler/Dave Burwell  
Investor Relations  
Toll Free: 1-888-221-0915  
Phone: (403) 221-0915  
[Info@howardgroupinc.com](mailto:Info@howardgroupinc.com)  
[www.howardgroupinc.com](http://www.howardgroupinc.com)